Our cohort was comprised of 20 patients with EGFR-mutant tumors, two patients with ALK-driven tumors, and two patients with non-EGFR and non-ALK mutated lung cancer (Fig. 2a). This evidence concerns the gene EGFR and lung carcinoma.